NetraMark Taps Ex-Scotiabank CEO Kevin Felix as Strategic Advisor
Event summary
- NetraMark Holdings Inc. appointed Kevin Felix, former President of Global Atlantic's Investment Office and ex-CEO of Scotiabank U.S., as Strategic Advisor on September 8, 2026.
- Felix brings 25+ years of experience in capital markets, asset management, and corporate strategy, with a background managing a $175 billion investment portfolio.
- He will advise on institutional investor relationships, strategic transactions, and capital markets strategy as NetraMark advances its commercialization efforts.
- Felix holds advanced degrees from Georgetown University Law Center and New York Law School, along with corporate governance experience as an independent director.
The big picture
NetraMark's appointment of Kevin Felix underscores its push to strengthen institutional relationships and capital markets strategy as it scales its AI-powered clinical trial solutions. The move comes amid growing demand for precision analytics in pharmaceutical R&D, where smaller datasets and patient heterogeneity pose significant challenges. Felix's background in managing large-scale investment portfolios and leading global financial operations positions NetraMark to navigate complex strategic transactions and investor engagements critical to its next phase of growth.
What we're watching
- Capital Markets Strategy
- How Kevin Felix's expertise will shape NetraMark's approach to institutional investor engagement and strategic transactions.
- Commercialization Pace
- Whether Felix's advisory role accelerates NetraMark's commercialization efforts in the pharmaceutical industry.
- Governance Dynamics
- The impact of Felix's corporate governance experience on NetraMark's long-term strategic direction.